IM Cannabis (IMCC) Other Non-Current Liabilities (2023 - 2024)
IM Cannabis' (IMCC) quarterly Other Non-Current Liabilities came in at $1.5 million in Q1 2024, down 26.31% quarter-over-quarter from $2.0 million in Q4 2023.
IM Cannabis (IMCC) Other Non-Current Liabilities (2023 - 2024) Analysis & Trends
IM Cannabis' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.5 million for Q1 2024.
- On a quarterly basis, Other Non-Current Liabilities changed N/A year-over-year to $1.5 million in Q1 2024; TTM through Mar 2024 was $1.5 million, a N/A change from a year earlier, with the FY2023 full-year figure at $2.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities retreated to $1.5 million in Q1 2024 per IMCC's latest filing, from $2.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.0 million in Q4 2023 and bottomed at $1.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 1.46 Mn |
| Dec 31, 2023 | 1.98 Mn |